Equine Myopathy Genetic Marker Detection for Early Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for accurately detecting inherited equine myopathies such as Polysaccharide Storage Myopathy, type 2 (PSSM2) and Myofibrillar Myopathy in horses, which are characterized by exercise intolerance and abnormal muscle biopsies, lacking effective genetic markers for early diagnosis.
Innovation Solution
A method involving the detection of specific nucleotide substitutions in the MYOT, FLNC, and MYOZ3 genes through sequencing and amplification of targeted exons to identify non-conservative amino acid substitutions in myotilin, filamin-C, and myozenin-3 proteins, using oligonucleotide probes and allele-specific PCR primers to determine the presence of biomarkers associated with these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods are used for equine myopathies, then muscle biopsy and exercise intolerance observation are required, but early and accurate diagnosis cannot be achieved
Solution Approach 1:
The patent performs genetic testing on blood or tissue samples to detect mutations in MYOT, FLNC, and MYOZ3 genes before clinical symptoms manifest. This preliminary genetic analysis enables early diagnosis of PSSM2 and MFM, eliminating the need to wait for muscle biopsy results or observe exercise intolerance symptoms before diagnosis.
2Adaptability or versatility
If genetic testing is performed on multiple genes simultaneously, then comprehensive biomarker detection is achieved, but test complexity increases
Solution Approach 1:
The patent divides the genetic testing process into three separate targeted analyses: MYOT gene testing for PSSM2, FLNC gene testing for MFM, and MYOZ3 gene testing. Each gene is amplified and sequenced independently using specific primers, allowing comprehensive multi-gene detection while maintaining manageable procedural complexity through modular testing approaches.
Data Source
AI summary
This disclosure describes detecting genetically distinct kinds of inherited myopathies in horses, variously referred to as Polysaccharide Storage Myopathy type 2 (PSSM2), Myofibrillar Myopathy (MFM), or idiopathic myopathy.